Trials / Completed
CompletedNCT02265536
A Study of LY3022855 In Participants With Breast or Prostate Cancer
Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6 weeks).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3022855 | Administered IV |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2017-11-03
- Completion
- 2017-11-03
- First posted
- 2014-10-16
- Last updated
- 2024-10-28
- Results posted
- 2024-10-28
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02265536. Inclusion in this directory is not an endorsement.